Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06244082 | Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping | PHASE2 | ACTIVE NOT_RECRUITING | 39 | — | — | Jan 22, 2024 | Jul 31, 2027 | May 14, 2025 | 10 | United States |
| Arm | Type | Description |
|---|---|---|
| AOC 1044 Multiple Dose Levels | EXPERIMENTAL | AOC 1044 will be IV infused every 6 weeks for approximately 2 years. |
| Name | Type | Description |
|---|---|---|
| AOC 1044 | DRUG | AOC 1044 will be administered via intravenous (IV) infusion |
Key Inclusion Criteria Rollover Participants: * Satisfactorily completed AOC 1044-CS1 (EXPLORE44) as determined by the Investigator and Sponsor * No significant tolerability issues with AOC 1044 De novo Participants: * Aged 7 to 27 years, inclusive, at the time of informed consent * Clinical dia...